NCT01681290View on ClinicalTrials.gov

Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2015

Conditions

Diabetic Peripheral Neuropathy

Interventions

DRUG

CBX129801

Trial Locations (29)

10032

New York

20502

Malmo

30033

Decatur

30318

Atlanta

48109

Ann Arbor

59701

Butte

68131

Omaha

75230

Dallas

77030

Houston

77074

Houston

78229

San Antonio

83404

Idaho Falls

89102

Las Vegas

90036

Los Angeles

90185

Umeå

90502

Torrance

92026

Escondido

92161

San Diego

92618

Irvine

92780

Tustin

93720

Fresno

94110

San Francisco

94598

Walnut Creek

02115

Boston

M5G 2C4

Toronto

H7T 2P5

Laval

413 45

Gothenburg

581 85

Linköping

171 76

Stockholm

Sponsors

Lead Sponsor

Cebix Incorporated

All Listed Sponsors

lead

Cebix Incorporated

INDUSTRY

NCT01681290 - Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter